Oxford BioMedica (LSE:OXB) shares fell 1.3% to 486.5 pence on Tuesday as investors continued to assess the cell and gene therapy specialist’s recently lowered revenue expectations and the implications for its near-term growth.
The shares remain substantially below their 52-week high of 950 pence, despite analysts maintaining broadly constructive longer-term views on the company. Investec, for example, has previously assigned Oxford BioMedica a Buy rating and a 772-pence price target, according to its published ratings history.
The disparity between the current share price and broker targets indicates continued optimism around the longer-term opportunity, although that has yet to provide a significant near-term catalyst.
Revenue Forecast Lowered Following Client Ordering Changes
Investor caution increased after Oxford BioMedica reduced its 2026 revenue guidance on 7 August.
The company now expects revenue of between £180 million and £200 million, down from its previous forecast of £220 million to £240 million.
Oxford BioMedica attributed the downgrade to short-term changes in customer ordering patterns alongside the phased ramp-up of its manufacturing operation in Durham, North Carolina.
The revised forecast has increased the focus on the timing of future client activity and the company’s ability to translate its longer-term growth opportunities into stronger revenue performance.
Durham Expansion Remains Central to US Growth
Oxford BioMedica has been investing in additional US manufacturing capacity as it seeks to expand its position in commercial-scale cell and gene therapy production.
The Durham facility, acquired from Resilience, is intended to strengthen the company’s commercial manufacturing capabilities in the US and provide capacity to meet anticipated growth in customer demand.
Progress at the site is therefore becoming an increasingly important factor for investors, particularly following the guidance reduction. Evidence of a successful production ramp-up could help provide greater confidence in Oxford BioMedica’s future revenue trajectory.
Customer Programme Timing Creates Revenue Volatility
Oxford BioMedica’s financial performance can also be affected by the timing and progression of individual customer programmes.
Projects moving through development and towards commercial manufacturing can result in fluctuations in activity and revenue between reporting periods, making customer ordering patterns an important driver of shorter-term performance.
For now, the shares remain caught between expectations for longer-term growth and more cautious near-term revenue assumptions. While existing analyst targets imply considerable potential upside from current levels, investors may look for evidence that customer ordering is improving and the Durham operation is scaling as expected before taking a more positive view of the stock.
Leave a Reply